OpenAI acquires Orchestra Bio to streamline drug development

What happened

We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients

Reported by 2 sources

The story so far

OpenAI said it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development. Its news announcement described the acquisition as in progress, while its later post on X said the deal was complete. OpenAI said it plans to build on Rosalind, its AI models and tools for life sciences research, to streamline drug-development operations and help new treatments reach patients. Mark Chen also welcomed Orchestra Bio to OpenAI as the company expands its work in AI-assisted drug discovery. Faster development and delivery of treatments are OpenAI’s stated goals for the acquisition.

Keep reading

Trending now

1. 1DeepSeek Open-Sources DeepInfer and API Components, With Model and Hardware Limits
2. 2Mistral Releases Voxtral 3 Speech Models, Voice Agents API and LiveKit-Based SDK
3. 4OpenAI Rolls Out Locked Chats in ChatGPT With PIN and Biometric Access
4. 5Perplexity Adds Fully Local Mac Operation to Computer